ReviewCancers2021
Radiolabeled PSMA Inhibitors.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05587192 (Radical Prostatectomy Without Prostate Biopsy Following 18F-PSMA-1007 PET/CT Based on a Diagnostic Model), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Radical Prostatectomy Without Prostate Biopsy Following 18F-PSMA-1007 PET/CT Based on a Diagnostic Model: a Single-center, Single-arm, Open-label Study
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Review
- Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025Review
- PET and SPECT Tracer Development via Copper-Mediated Radiohalogenation of Divergent and Stable Aryl-Boronic Esters.Pharmaceutics · 2025Article
- Prodrugs Targeting Prostate-Specific Membrane Antigen against Prostate Cancer.Journal of medicinal chemistry · 2025Review
- Enhancing the radionuclide theranostic concept through the radiohybrid approach.RSC medicinal chemistry · 2025Review
- Fully Automated Production of (((Pharmaceuticals (Basel, Switzerland) · 2025Article
- Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.Molecules (Basel, Switzerland) · 2024Review
- Improvement of End-of-Synthesis Radiochemical Purity ofPharmaceutics · 2024Article
- Synthesis and Preclinical Evaluation of a Bispecific PSMA-617/RM2 Heterodimer Targeting Prostate Cancer.ACS medicinal chemistry letters · 2024Article
- Article
- Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled withACS pharmacology & translational science · 2024Article
- Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection.Theranostics · 2024Review
- Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review.Frontiers in oncology · 2024Review
- Preclinical Evaluation of a Novel High-Affinity Radioligand [International journal of molecular sciences · 2023Article
- Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy.Cancers · 2023Review
- The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making-The Urological Perspective.Cancers · 2023Review
- Article
- The epigenetic function of androgen receptor in prostate cancer progression.Frontiers in cell and developmental biology · 2023Review
- [European journal of nuclear medicine and molecular imaging · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PSMA has shown to be a promising target for diagnosis and therapy (theranostics) of prostate cancer. We have reviewed developments in the field of radio- and fluorescence-guided surgery and targeted photodynamic therapy as well as multitargeting PSMA inhibitors also addressing albumin, GRPr and integrin α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.